Author/Authors :
Wei, Yali Institute of Nutrition and Food Hygiene - School of Public Health - Shandong University, Jinan, China , Wang, Shuli Department of Medical Imaging - Shandong Provincial Hospital Affiliated of Shandong University, Jinan, China , Meng, Yan Department of Nutrition - Shandong Provincial Hospital Affiliated of Shandong University, Jinan, China , Yu, Qingtao Department of Endocrinology - The People Hospital of Huaiyin Jinan, Jinan, China , Wang, Qian Department of Nutrition - Shandong Provincial Hospital Affiliated of Shandong University, Jinan, China , Xu, Hongzhao Institute of Nutrition and Food Hygiene - School of Public Health - Shandong University, Jinan, China , Yuan, Huacai Institute of Nutrition and Food Hygiene - School of Public Health - Shandong University, Jinan, China , Li, Xiaoxu Department of Nutrition - Shandong Provincial Hospital Affiliated of Shandong University, Jinan, China , Chen, Liyong Department of Nutrition - Shandong Provincial Hospital Affiliated of Shandong University, Jinan, China
Abstract :
Context: Vitamin D (VD) has been found to play a key role in nonalcoholic fatty liver disease (NAFLD). This meta-analysis explored
the effects of VD supplementation in patients with NAFLD.
Methods: The PubMed, EMBASE, and the Cochrane Library databases were searched to find randomized control trials (RCTs) that
measured the changes between the VD supplement group and the control group until May 2019. Standard mean difference (SMD)
with 95% confidence intervals (CI) was calculated when data units were different, otherwise weighted mean difference (WMD) and
95% CI was calculated. Heterogeneity was assessed using the I2 statistic.
Results: Eight RCTs with 624 individuals were extracted. The main indicators, including serum alanine aminotransferase (WMD =
-0.052; 95% CI: -3.740, 3.636; P = 0.978) and aspartate aminotransferase concentrations (WMD = -0.479; 95% CI: -2.791, 1.833; P = 0.685)
were not significantly different between the intervention and placebo groups. In addition, no significant intergroup difference was
observed in the following secondary indicators: fasting blood glucose (WMD = 0.466; 95% CI: -5.313, -10.879; P = 0.061), homeostasis
model assessment (WMD = 0.380, 95% CI: -0.162, 0.923; P = 0.169), serum insulin concentration (WMD = 0.760; 95% CI: -0.532, 2.052; P
= 0.249), high-density lipoprotein (WMD = -0.012; 95% CI: -0.188, 0.164; P = 0.891), and low-density lipoprotein (WMD = -0.115; 95% CI:
-3.849, -3.620; P = 0.952).
Conclusions: The results indicate thatVDsupplementation does not improve liver enzymes, insulin resistance, glucose metabolism
parameters, and lipid levels in patients with NAFLD.
Keywords :
Meta-Analysis , Supplementation , Vitamin D , Nonalcoholic Fatty Liver Disease
